Implant Traceability in Argentina: Resolución M.S. 2175/2013 and GS1

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Argentina’s traceability system for medical products was established by Resolución M.S. 2175/2013 of the Ministry of Health. Phase one applies to eight categories of implantable medical devices: (1) cardiac defibrillators/cardioverters; (2) cochlear electronic hearing stimulators; (3) intraocular lenses; (4) cardiac pacemakers; (5) internal breast prostheses; (6) coronary vascular stents; (7) hip joint prostheses; (8) spinal prostheses.

Coding requirements: the outer packaging of each unit must carry a carrier capable of storing a unique code according to GS1 standards, containing four pieces of information: GTIN (Global Trade Item Number), serial number (up to 20 alphanumeric characters), batch number, and expiry date (where applicable, encoded in DD/MM/YY format). The registration holder must also register in the national medical products traceability system database administered by ANMAT, identified through the GLN (Global Location Number) granted by GS1 Argentina. Two separate identifiers therefore work together: the product code travels on the packaging, and the location code identifies the parties sending and receiving the goods.

For foreign manufacturers, the operational burden is best understood as three workstreams that must converge on the first shipment: product coding, entity identification, and database registration. Product coding is the GTIN and serial number work on the packaging; entity identification is the GLN obtained from GS1 Argentina; database registration is the filing under Disposición 2303/2014 through which the registration holder enters the system. None of the three can substitute for another, and a delay in any one of them stalls the compliance of a listed product, whatever the state of the other two.

2. Legal basis

RegulationReference / numberPublication dateProvisions
Traceability system (phase one, implantable devices)Resolución M.S. 2175/20132013Phase one product list provision; GS1 coding provision
Traceability database registrationDisposición ANMAT 2303/20142014Database registration provision; GLN identification provision
MERCOSUR technical regulation on medical device registrationGMC/RES 25/21October 13, 2021Annex II rule 8 (implant classification)

3. Expert insights

Insight 1: A list-based phase one means implants not on the list are not yet covered. The eight-category list is a closed enumeration; other implantable devices, such as hernia repair meshes and certain orthopedic products, are currently outside the scope of phase one. Companies should check product by product against the list rather than self-expanding the scope on the broad criterion of whether the device is implanted. Over-application wastes coding and registration effort on products with no current obligation, while under-application on a listed product creates an immediate violation. The list is also the document to monitor, since expansion would pull new product lines into scope.

Insight 2: The 20-character serial number limit is a hard technical constraint. This constraint directly affects the design of a company’s coding rules. If the existing serial number scheme exceeds 20 characters, it must be redesigned before export, and the new scheme must be synchronized with changes in both the production system and the label printing system. This is not a label-level adjustment but a change that propagates through manufacturing execution, packaging lines, and any downstream systems that log serial numbers, so the engineering lead time should be planned well before the first Argentine shipment.

Insight 3: The GLN is a location code assigned to the sending and receiving parties, separate from the product code. The registration holder must first obtain a GLN from GS1 Argentina, then register in the database, and link the logistics information, namely the recipient code GLN/CUFE, dates, invoices, and delivery notes, with the product-side codes. This is the coordination of two coding systems, not a single coding exercise. Companies that plan only the product-side GTIN work discover late that the distribution-side identifiers, the reporting format, and the linkage between shipments and product codes constitute a separate workstream with its own dependencies.

Insight 4: Traceability data is only as reliable as the discipline of the parties reporting it. The system links product codes to logistics records in real time, which means an error in a shipment record, a wrong recipient code or a missing delivery note reference, is not a clerical issue but a break in the chain that the database records permanently. Because the registration holder is the party of record, manufacturers should align their distributors and logistics partners on the reporting fields and timelines before launch, and should reconcile reported data against actual shipments periodically. A periodic reconciliation of invoices and delivery notes against database entries catches drift early, while ad hoc corrections after an ANMAT query expose both the data gap and the absence of monitoring around it.

4. Practical recommendations

  1. Check the eight-category list item by item. Confirm whether the product is listed; only listed products start traceability preparation, while unlisted products can be deferred but should remain under tracking, since the list may expand.
  2. Redesign the serial number scheme first. Confirm that existing serial numbers do not exceed 20 alphanumeric characters; if they do, modify production and label systems in sync.
  3. Apply for GS1 codes early. Apply to GS1 Argentina for the GLN and complete GTIN assignment on the product side; neither can be arranged at the last minute.
  4. Complete database registration under Disposición 2303/2014. The registration holder handles the registration, then reports logistics information in real time and links it with the product-side codes.

5. Verification checklist

  • □ Products have been checked item by item against the eight-category list of Resolución 2175/2013
  • □ Outer packaging carries a unique code carrier according to GS1 standards
  • □ Serial numbers do not exceed 20 alphanumeric characters
  • □ The expiry date is encoded in DD/MM/YY format where applicable
  • □ The GLN from GS1 Argentina has been applied for and obtained
  • □ Database registration under Disposición 2303/2014 has been completed
  • □ A reporting process for logistics information, namely GLN/CUFE, dates, invoices, and delivery notes, has been established

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience, tracking the developments of regulators worldwide. All external content follows the drafting standard of conclusions first, traceable basis, and verifiable numbers. For a market access plan tailored to your specific product for Argentina or the MERCOSUR region, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail